Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 7ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Cyclophosphamide 3Calcium Dobesilate 3Bortezomib 3Clinical Protocols 2venetoclax 1siltuximab 1pomalidomide 1isatuximab 1daratumumab 1X-Rays 1Valganciclovir 1Therapeutics 1Specimen Handling 1Polymerase Chain Reaction 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1MLN2238 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Biopsy 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Immunoglobulin Light-chain Amyloidosis × siltuximab × Clear all
NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡